Pages that link to "Q33824842"
Jump to navigation
Jump to search
The following pages link to Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study (Q33824842):
Displaying 50 items.
- Infracentimetric HER-2 positive breast tumours-review of the literature (Q26774597) (← links)
- Toward precision medicine of breast cancer (Q28073967) (← links)
- Treatment of early-stage HER2+ breast cancer-an evolving field (Q28081124) (← links)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (Q35038093) (← links)
- Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer (Q35674829) (← links)
- Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study (Q35688776) (← links)
- The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer (Q35764604) (← links)
- Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials (Q35947005) (← links)
- SEOM clinical guidelines in early-stage breast cancer 2015 (Q36400320) (← links)
- Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinoma (Q36476168) (← links)
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer (Q36862936) (← links)
- Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer (Q37077443) (← links)
- Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer (Q37120868) (← links)
- Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer. (Q37138269) (← links)
- Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion. (Q37665618) (← links)
- Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach? (Q38262886) (← links)
- The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer (Q38295108) (← links)
- Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors (Q38552449) (← links)
- Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a,bN0 Breast Cancer (Q38619005) (← links)
- The evolving understanding of small HER2-positive breast cancers: matching management to outcomes (Q38658647) (← links)
- Adjuvant trastuzumab: a 10-year overview of its benefit. (Q39018742) (← links)
- Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab (Q39532324) (← links)
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. (Q40353199) (← links)
- Recurrence risk perception and quality of life following treatment of breast cancer (Q40412658) (← links)
- Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer (Q40583931) (← links)
- Follow-up of Patients Treated for pT1aN0M0 Breast Cancer: 10-year Survival and Prognostic Factors (Q40877409) (← links)
- Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). (Q41012013) (← links)
- Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis (Q45284997) (← links)
- Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors (Q46841562) (← links)
- Clinicopathological features and survival of early stage breast cancer in northwest China: A population-based retrospective study of 1287 patients (Q47252563) (← links)
- The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence (Q48015694) (← links)
- Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells (Q48154822) (← links)
- Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer (Q48202060) (← links)
- Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. (Q48281067) (← links)
- Exogenous reproductive hormone use in breast cancer survivors and previvors (Q49864111) (← links)
- Management of small T1a/b breast cancer by tumor subtype (Q50875498) (← links)
- The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer (Q51673307) (← links)
- Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). (Q53521179) (← links)
- [Is the waiver of chemotherapy for small, node-negative breast cancer justified? ]. (Q53599122) (← links)
- The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer. (Q55094642) (← links)
- Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer? (Q57053294) (← links)
- Update on adjuvant chemotherapy for early breast cancer (Q57126532) (← links)
- Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer (Q60937739) (← links)
- Construction of prognostic microRNA signature for human invasive breast cancer by integrated analysis (Q64089643) (← links)
- Omitting Adjuvant Radiotherapy for Hormone Receptor‒Positive Early-Stage Breast Cancer in Old Age: A Propensity Score Matched SEER Analysis (Q88630599) (← links)
- Accuracy of a nomogram to predict the survival benefit of surgical axillary staging in T1 breast cancer patients (Q89311063) (← links)
- Regulation of Hippo signaling and triple negative breast cancer progression by an ubiquitin ligase RNF187 (Q90542934) (← links)
- KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer (Q91859346) (← links)
- Comprehensive identification and characterization of somatic copy number alterations in triple‑negative breast cancer (Q92366743) (← links)
- Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer (Q92541523) (← links)